ProMetic Enter Into Long-Term Supply Agreement With Halozyme

Halozyme (Halozyme) and ProMetic Life Sciences (ProMetic) have entered into a long-term supply agreement for a proprietary synthetic ligand affinity adsorbent manufactured by ProMetic’s UK subsidiary, ProMetic BioSciences.

Reportedly, the agreement is for an initial five-year term with the opportunity for future extension. Other aspects of the agreement were not disclosed for reasons of client confidentiality.

The synthetic ligand adsorbent provided under the supply agreement is used by Halozyme in the manufacture of its rHuPH20 product, a recombinant version of human hyaluronidase enzyme.

The company said that ProMetic’s synthetic ligand adsorbent has been used by Halozyme throughout the development of rHuPH20 and for manufacture of this FDA-approved product.

Hyaluronidase temporarily degrades hyaluronan, a space-filling, gel-like substance that is an important structural component of tissues throughout the body, such as skin and cartilage. The enzyme is used to facilitate the penetration and diffusion of other drugs and fluids that are injected under the skin or in the muscle.

Steve Burton, CEO of ProMetic, said: “The signing of this long-term supply agreement reflects the increasing importance of ProMetic’s synthetic ligand product to Halozyme’s manufacture of rHuPH20 and the need for Halozyme to establish a secure supply chain. The market for Halozyme’s rHuPH20 product is expanding and ProMetic is proud to support Halozyme’s manufacturing process for this innovative product.”